Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 101 to 125 of 797

TitleReference numberPublishedLast updated
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA929
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodineTA928
Ranibizumab for treating diabetic macular oedemaTA274
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Tirzepatide for treating type 2 diabetesTA924
Mirikizumab for treating moderately to severely active ulcerative colitisTA925
Baricitinib for treating severe alopecia areataTA926
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)TA923
Rimegepant for treating migraineTA919
Tofacitinib for treating active ankylosing spondylitisTA920
Ruxolitinib for treating polycythaemia veraTA921
Daridorexant for treating long-term insomniaTA922
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA927
Bimekizumab for treating axial spondyloarthritisTA918
Pegunigalsidase alfa for treating Fabry diseaseTA915
Bimekizumab for treating active psoriatic arthritisTA916
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathyTA913
Semaglutide for managing overweight and obesityTA875
Cipaglucosidase alfa with miglustat for treating late-onset Pompe diseaseTA912
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)TA910
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancerTA909
Rimegepant for preventing migraineTA906
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapyTA908

Results per page

  1. 10
  2. 25
  3. 50
  4. All